707-AP peptide recognized by human antibody induces human leukocyte antigen A2-restricted cytotoxic T lymphocyte killing of melanoma

Clinical Cancer Research

Volumn 3, Issue 8, 1997, Pages 1363-1370

  Takahashi, Takenori ^a   Irie, Reiko F ^a   Nishinaka, Yumiko ^a   Hoon, Dave S B ^a  

^a John Wayne Inst Cancer Treatm Res   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HLA ANTIGEN CLASS 2; MONOCLONAL ANTIBODY; SYNTHETIC PEPTIDE; TUMOR ANTIGEN;

ANTIGEN RECOGNITION; ARTICLE; CELL KILLING; CYTOTOXIC T LYMPHOCYTE; CYTOTOXICITY; HUMAN; HUMAN CELL; MAJOR CLINICAL STUDY; MELANOMA; PRIORITY JOURNAL;

AMINO ACID SEQUENCE; ANTIBODIES, MONOCLONAL; ANTIBODY SPECIFICITY; BINDING SITES, ANTIBODY; CYTOTOXICITY, IMMUNOLOGIC; HLA-A2 ANTIGEN; HUMANS; MELANOMA; NEOPLASM METASTASIS; NEOPLASM STAGING; OLIGOPEPTIDES; STRUCTURE-ACTIVITY RELATIONSHIP; T-LYMPHOCYTES, CYTOTOXIC; TUMOR CELLS, CULTURED;

EID: 0030839839     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (38)

1. Oka, T., Kikumoto, Y., Itakura, K., Morton, D. L., and Irie, R. F. A human monoclonal antibody identified an immunoreactive tetrapeptide sequence (Lys-Try-Gln-Ile) in 43-kDa protein of human melanoma. Cancer Res., 54: 3511-3515, 1994.
2. Morioka, N., Kikumoto, Y., Oka, T., Hoon, D. S. B., Morton, D. L., and Irie, R. F. A decapeptide (Gln-Asp-Leu-Thr-Met-Lys-Tyr-Gln-Ile-Phe) from human melanoma is recognized by CTL in melanoma patients. J. Immunol., 15: 5650-5658, 1994.
3. Morioka, N., Kikumoto, Y., Hoon, D. S. B., Morton, D. L., and Irie, R. F. Cytotoxic T-cell recognition of a human melanoma-derived peptide with a carboxyl-terminal alanine-proline sequence. Mol. Immunol., 32: 573-581, 1995.
4. Kikumoto, Y., Oka, T., Cao, J-N., Sze, L., and Irie, R. F. Peptides with carboxyl-terminal sequence of alanine-proline: detection by a human monoclonal antibody. Hybridoma, 14: 45-50, 1995.
5. Van der Bruggen, P., Traversari, C., Chomez, P., Lurquin, C., De Plaen, E., Van den Eynde, B., Knuth, A., and Boon, T. A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. Science (Washington DC), 254: 1643-1647, 1991.
6. Rivoltini, L., Kawakami, Y., Sakaguchi, K., Southwood, S., Sette, A., Robbins, P. F., Marincola, F. M., Salgaller, M. L., Yannelli, J. R., Appella, E., and Rosenberg, S. A. Induction of tumor-reactive CTL from peripheral blood and tumor-infiltrating lymphocytes of melanoma patients by in vitro stimulation with an immunodominant peptide of the human melanoma antigen MART-1. J. Immunol., 154: 2257-2265, 1995.
7. Mittleman, A. Z., Chen, J., Yang, H., Wong, G. Y., and Ferrone, S. Human high molecular weight melanoma-associated antigen (HMW-TAA) mimicry by mouse anti-idiotypic monoclonal antibody MK2-23: induction of humoral anti-HMV-TAA immunity and prolongation of survival in patients with stage IV melanoma. Proc. Natl. Acad. Sci. USA, 89: 466-470, 1992.
8. Tai, T., Paulson, J. C., Cahan, C. D., and Irie, R. F. Ganglioside GM2 as a human tumor antigen (OFA-1-2). Proc. Natl. Acad. Sci. USA, 80: 5392-5396, 1983.
9. Cahan, L. D., Irie, R. F., Singh, R., Cassidenti, A., and Paulson, J. C. Identification of a human neuroectodermal tumor antigen (OFA-1-1) as ganglioside GD2. Proc. Natl. Acad. Sci. USA, 79: 7629-7633, 1982.
10. Celis, E., Tsai, V., Crimi, C., DeMars, R., Wentworth, P. A., Chestnut, R. W., Grey, H. M., Sette, A., and Serra, H. M. Induction of anti-tumor cytotoxic T lymphocytes in normal humans using primary cultures and synthetic peptide epitopes. Proc. Natl. Acad. Sci. USA, 91: 2105-2109, 1994.
11. Van den Eynde, B., Peeters, O., De Backer, O., Gaugler, B., Lucas, S., and Boon, T. A new family of gene coding for an antigen recognized by autologous cytotoxic T lymphocytes on a human melanoma. J. Exp. Med., 182: 689-698, 1995.
12. Boel, P., Wildman, C., Sensi, M. L., Brasseur, R., Renauld, J. C., Coulie, P., Boon, T., and Van der Bruggen, P. BAGE: a new gene encoding an antigen recognized on human melanomas by cytolytic T lymphocytes. Immunity, 2: 167-175, 1995.
13. Boon, T., Cerottini, J. C., Van den Eynde, B., Van der Bruggen, P., and Van Pel, A. Tumor antigens recognized by T lymphocytes. Annu. Rev. Immunol., 12: 337-365, 1994.
14. Cox, A. L., Skipper, J., Chen, Y., and Henderson, R. A. Identification of a peptide recognized by five melanoma-specific human cytotoxic T cell lines. Science (Washington DC), 264: 716-719, 1994.
15. Romero, P., Pannetier, C., Herman, J., Victor Jongeneel, C., Cerottini, J-C., and Coulie, P. G. Multiple specificities in the repertoire of a melanoma patient's cytolytic T lymphocytes directed against tumor antigen MAGE-1. J. Exp. Med., 182: 1019-1028, 1995.
16. Fleischauer, K., Tanzarel, S. A., Walley, H-J., Bordignon, C., and Traversari, C. Multiple HLA-A alleles can present an immunodominant peptide of the human melanoma antigen Melan-A/MART-1 to a peptide-specific HLA-A*201+ cytotoxic T cell line. J. Immunol., 157: 787-797, 1996.
17. Rivoltini, L., Loftus, D. J., Barracchini, K., Arienti, F., Mazzochi, A., Biddison, W. E., Salgaller, M. L., Appella, E., Parmiani, G., and Marinocola, F. M. Binding and presentation of peptides derived from melanoma antigens MART-1 and glycoprotein-100 of HLA A2 subtypes. J. Immunol., 156: 3882-3891, 1996.
18. Morton, D. L., Foshag, L. J., Hoon, D. S. B, Nizze, J. A., Wanek, L. A., Chang, C., Davtyan, D. G., Gupta, R. K., Elashoff, R., and Irie, R. F. Prolongation of survival in metastatic melanoma after active specific immunotherapy with a new polyvalent melanoma vaccine. Ann. Surg., 216: 463-482, 1992.
19. Livingston, P. O. Approaches to augmenting the IgG antibody response to melanoma ganglioside vaccines. Ann. NY Acad. Sci., 690: 204-213, 1993.
20. Hoon, D. S. B., and Irie, R. F. Current status of human melanoma vaccines. In: Bio Drugs, 1: 66. Adis International Ltd., 1997.
21. Rammensee, H. G., Falk, K., and Rozschke, O. Peptides naturally presented by MHC class I molecules. Annu. Rev. Immunol., 11: 213-244, 1993.
22. Rammensee, H-G., Friede, T., and Stevanovic, S. MHC ligands and peptide motifs: first listing. Immunogenetics, 41: 178-228, 1995.
23. Sidney, J., Grey, H. M., Kubo, R. T., and Sette, A. Practical, biochemical, and evolutionary implications of the discovery of HLA class I supermotifs. Immunol. Today, 17: 261-266, 1966.
24. Zweernink, H. J., Gammon, M. C., Utz, U., Sauma, S. Y., Harrer, T., Hawkins, J. C., Johnson, R. P., Sirotina, A., Hermes, J. D., Walker, B. D., and Biddison, W. E. Presentation of endogenous peptides to MHC class I restricted cytotoxic T lymphocytes in transport deletion mutant T2 cells. J. Immunol., 150: 1763-1771, 1993.
25. Hayashi, Y., Hoon, D. S., Park, M. S., Terasaki, P. I., and Morton, D. L. Induction of CD4+ cytotoxic T cells by sensitization with allogeneic melanomas bearing shared or cross-reactive HLA-A. Cell. Immunol., 139: 411-425, 1992.
26. Hoon, D. S. B., Ando, I., Sviland, G., Tsuchida, T., Okun, E., Morton, D. L., and Irie, R. F. Ganglioside GM2 expression on human melanoma cells correlates with sensitivity to lymphokine-activated killer cells. Int. J. Cancer, 43: 857-862, 1989.
27. Hoon, D. S. B., Bowker, R. J., and Cochran, A. J. Suppressor cell activity in melanoma-draining lymph nodes. Cancer Res., 47: 1529-1533, 1987.
28. Muller, G., Saloga, J., Germann, T., Bellinghausen, I., Mohamadzadeh, M., Knop, J., and Enk, S. H. Identification and induction of human keratinocyte-derived IL-12. J. Clin. Invest., 94: 1799-1805, 1994.
29. Katano, M., Jien, M., and Irie R. F. Human monoclonal antibody to ganglioside GD2-inhibited human melanoma xenograft. Eur. J. Cancer, 20: 1053-1059, 1984.
30. Hoon, D. S. B., Hayashi, Y., Morisaki, T., Foshag, L. J., and Morton, D. L. Interleukin 4 plus tumor necrosis factor α augments the antigenicity of melanoma cells. Cancer Immunol. Immunother., 37: 378-384, 1993.
31. Hoon, D. S. B., Yuzuki, D., Hayashida, M., and Morton, D. L. Melanoma patients immunized with melanoma cell vaccine induce antibody responses to recombinant MAGE-1 antigen. J. Immunol., 154: 730-737, 1995.
32. Tiwaran, J. L., and Teraski, P. I. The HLA complex. In: HLA and Disease Associations. New York: Springer-Verlag, 1985.
33. Hayashi, Y., Hoon, D. S. B., Foshag, L. J., Park, M. S., Terasaki, P. I., and Morton, D. L. A preclinical model to assess the antigenicity of an HLA-A2 melanoma cell vaccine. Cancer (Phila.), 72: 750-759, 1993.
34. Ioannides, C. G., Fisk, B., Jerome, K. R., Irimura, K. R., Whaton, J. T., and Finn, O. J. J. Immunol. 151: 3693-3703, 1993.
35. Imanishi, T., and Gojobori, T. Patterns of nucleotide substitutions inferred from the phylogenies of the class I major histocompatibility complex genes. J. Mol. Evol., 35: 196-204, 1992.
36. Peoples, G. E., Goedegebuure, P. S., Andrews, J. V. R., Schoof, D. D., and Eberlein, T. J. HLA-A2 presents shared tumor-associated antigens derived from endogenous proteins in ovarian cancer. J. Immunol., 151: 5481-5491, 1993.
37. Mandelboim, O., Vafai, E., Fridkin, M., Katz-Hillel, A., Feldman, M., Berke, G., and Eisenbach, L. Regression of established murine carcinoma metastases following vaccination with tumor-associated antigen peptides. Nat. Med., 1: 1179-1183, 1995.
38. Feltkamp, M. C., Smits, H. L., Vierboom, M. P., Minnaar, R. P., de Jongh, B. M., Drijfhout, J. W., ter Schegget, J., Melief, C. J., and Kast, W. M. Vaccination with cytotoxic T lymphocyte epitope-containing peptide protects against a tumor induced by human papillomavirus type 16-transformed cells. Eur. J. Immunol., 23: 2242-2249, 1993.